Breaking Down Bristol-Myers Squibb Company (BMY) Financial Health: Key Insights for Investors

Breaking Down Bristol-Myers Squibb Company (BMY) Financial Health: Key Insights for Investors

US | Healthcare | Drug Manufacturers - General | NYSE

Bristol-Myers Squibb Company (BMY) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Bristol-Myers Squibb Company (BMY) Revenue Streams

Revenue Analysis

Bristol-Myers Squibb Company reported total revenue of $49.0 billion in 2023, with a year-over-year growth of 6%.

Key Revenue Sources 2023 Revenue Percentage of Total Revenue
Oncology Portfolio $24.3 billion 49.6%
Immunology Segment $8.7 billion 17.8%
Cardiovascular Portfolio $6.5 billion 13.3%

Revenue Geographical Breakdown

Region 2023 Revenue Growth Rate
United States $33.6 billion 7.2%
Europe $8.9 billion 4.5%
Rest of World $6.5 billion 5.8%

Top Performing Products

  • Eliquis (anticoagulant): $13.8 billion in 2023
  • Opdivo (cancer immunotherapy): $8.2 billion in 2023
  • Yervoy (cancer immunotherapy): $2.6 billion in 2023

Research and development investments totaled $7.3 billion in 2023, representing 14.9% of total revenue.




A Deep Dive into Bristol-Myers Squibb Company (BMY) Profitability

Profitability Metrics Analysis

Financial performance reveals critical insights into the company's profitability landscape as of 2024.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin 79.4% 78.2%
Operating Profit Margin 32.6% 30.1%
Net Profit Margin 25.3% 23.7%

Key profitability highlights include:

  • Gross profit for 2023: $23.7 billion
  • Operating income: $14.2 billion
  • Net income: $11.4 billion

Operational efficiency metrics demonstrate strategic cost management:

Efficiency Metric 2023 Performance
Operating Expense Ratio 46.8%
Research & Development Expense $7.6 billion

Industry comparative analysis reveals competitive positioning:

  • Pharmaceutical sector average gross margin: 68.5%
  • Peer group operating margin: 29.3%
  • Return on Equity (ROE): 22.7%



Debt vs. Equity: How Bristol-Myers Squibb Company (BMY) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.

Debt Overview

Debt Category Amount (in billions)
Total Long-Term Debt $27.4
Short-Term Debt $4.6
Total Debt $32.0

Debt-to-Equity Metrics

  • Debt-to-Equity Ratio: 1.45
  • Industry Average Debt-to-Equity Ratio: 1.32
  • Credit Rating: BBB+

Recent Debt Financing Activities

Debt Issuance Amount Interest Rate
Senior Notes $3.5 billion 4.25%
Convertible Bonds $2.1 billion 3.75%

Capital Structure Breakdown

  • Equity Financing: $45.6 billion
  • Debt Financing: $32.0 billion
  • Debt-to-Capital Ratio: 41.2%



Assessing Bristol-Myers Squibb Company (BMY) Liquidity

Liquidity and Solvency Analysis

Financial analysis reveals critical insights into the company's liquidity and solvency positioning as of 2024.

Liquidity Ratios

Liquidity Metric 2024 Value
Current Ratio 1.42
Quick Ratio 1.18
Working Capital $8.3 billion

Cash Flow Analysis

Cash Flow Category 2024 Amount
Operating Cash Flow $15.7 billion
Investing Cash Flow $-4.2 billion
Financing Cash Flow $-6.9 billion

Key Liquidity Indicators

  • Cash and Cash Equivalents: $12.4 billion
  • Short-Term Investments: $3.6 billion
  • Total Liquid Assets: $16 billion

Debt and Solvency Metrics

Solvency Indicator 2024 Value
Total Debt $25.6 billion
Debt-to-Equity Ratio 1.37
Interest Coverage Ratio 4.9x



Is Bristol-Myers Squibb Company (BMY) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

Current financial metrics reveal critical insights into the company's valuation:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio 11.3x
Price-to-Book (P/B) Ratio 2.7x
Enterprise Value/EBITDA 9.6x
Dividend Yield 4.9%

Stock price performance highlights:

  • 12-month stock price range: $54.22 - $77.54
  • Current stock price: $68.35
  • Year-to-date performance: +12.7%

Analyst recommendations breakdown:

Recommendation Percentage
Buy 58%
Hold 35%
Sell 7%

Additional valuation insights:

  • Average target price: $75.40
  • Potential upside: 10.3%
  • Payout ratio: 32.5%



Key Risks Facing Bristol-Myers Squibb Company (BMY)

Risk Factors: Comprehensive Analysis

The pharmaceutical and biotechnology sector presents complex risk landscapes with multifaceted challenges.

Key Operational Risks

  • Research and Development Investment Risk: $7.1 billion annual R&D expenditure with potential clinical trial failures
  • Patent Expiration Risk: Potential revenue loss from generic competition
  • Global Supply Chain Disruption Vulnerability

Financial Risk Matrix

Risk Category Potential Impact Mitigation Strategy
Regulatory Compliance $500 million potential compliance penalty exposure Enhanced legal and regulatory monitoring
Market Competition 15% potential market share reduction Continuous product pipeline development
Currency Fluctuation $250 million potential foreign exchange risk Hedging financial instruments

Strategic Risk Assessment

Key strategic risks include:

  • Emerging market expansion challenges
  • Technological disruption in pharmaceutical research
  • Intellectual property protection complexity

Regulatory Risk Landscape

Pharmaceutical regulatory environment characterized by:

  • FDA approval process complexity
  • International market access restrictions
  • Evolving healthcare policy frameworks

Cybersecurity and Data Protection Risks

Potential cybersecurity breach impact: $100 million estimated potential financial exposure




Future Growth Prospects for Bristol-Myers Squibb Company (BMY)

Growth Opportunities

The pharmaceutical company demonstrates robust growth potential across multiple strategic dimensions in 2024.

Key Growth Drivers

  • Oncology pipeline with 8 potential new molecular entities
  • Immunology research focusing on 5 breakthrough therapeutic areas
  • Global market expansion strategies targeting emerging pharmaceutical markets

Revenue Growth Projections

Year Projected Revenue Growth Percentage
2024 $48.3 billion 6.2%
2025 $51.7 billion 7.0%
2026 $55.4 billion 7.5%

Strategic Partnerships

  • Research collaboration with 3 leading academic institutions
  • Strategic alliance with 2 biotechnology companies
  • Investment in digital health technologies: $320 million

Competitive Advantages

Research and development investment: $7.2 billion in 2024

R&D Focus Area Investment Allocation
Oncology 42%
Immunology 28%
Cardiovascular 18%
Neuroscience 12%

DCF model

Bristol-Myers Squibb Company (BMY) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.